352 related articles for article (PubMed ID: 19962268)
21. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
[TBL] [Abstract][Full Text] [Related]
22. FDG-PET/CT in the diagnosis of recurrent breast cancer.
Murakami R; Kumita S; Yoshida T; Ishihara K; Kiriyama T; Hakozaki K; Yanagihara K; Iida S; Tsuchiya S
Acta Radiol; 2012 Feb; 53(1):12-6. PubMed ID: 22067206
[TBL] [Abstract][Full Text] [Related]
23. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.
Riegger C; Herrmann J; Nagarajah J; Hecktor J; Kuemmel S; Otterbach F; Hahn S; Bockisch A; Lauenstein T; Antoch G; Heusner TA
Eur J Nucl Med Mol Imaging; 2012 May; 39(5):852-63. PubMed ID: 22392069
[TBL] [Abstract][Full Text] [Related]
24. Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer.
Bellomi M; Rizzo S; Travaini LL; Bazzi L; Trifirò G; Zampino MG; Radice D; Paganelli G
Radiol Med; 2007 Aug; 112(5):681-90. PubMed ID: 17657420
[TBL] [Abstract][Full Text] [Related]
25. [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers].
Xing Y; Zhao JH; Wang TS; Qiao WL; Che WJ
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):129-33. PubMed ID: 19538891
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
Koolen BB; Vrancken Peeters MJ; Aukema TS; Vogel WV; Oldenburg HS; van der Hage JA; Hoefnagel CA; Stokkel MP; Loo CE; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
[TBL] [Abstract][Full Text] [Related]
27. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
[TBL] [Abstract][Full Text] [Related]
28. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
29. Breast cancer staging in a single session: whole-body PET/CT mammography.
Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
[TBL] [Abstract][Full Text] [Related]
30. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer.
Eubank WB; Mankoff D; Bhattacharya M; Gralow J; Linden H; Ellis G; Lindsley S; Austin-Seymour M; Livingston R
AJR Am J Roentgenol; 2004 Aug; 183(2):479-86. PubMed ID: 15269044
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
32. 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer.
Eubank WB; Mankoff DA; Takasugi J; Vesselle H; Eary JF; Shanley TJ; Gralow JR; Charlop A; Ellis GK; Lindsley KL; Austin-Seymour MM; Funkhouser CP; Livingston RB
J Clin Oncol; 2001 Aug; 19(15):3516-23. PubMed ID: 11481358
[TBL] [Abstract][Full Text] [Related]
33. FDG PET/CT in the detection of recurrent rectal cancer.
Kau T; Reinprecht P; Eicher W; Lind P; Starlinger M; Hausegger KA
Int Surg; 2009; 94(4):315-24. PubMed ID: 20302028
[TBL] [Abstract][Full Text] [Related]
34. ¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.
Groheux D; Cochet A; Humbert O; Alberini JL; Hindié E; Mankoff D
J Nucl Med; 2016 Feb; 57 Suppl 1():17S-26S. PubMed ID: 26834096
[TBL] [Abstract][Full Text] [Related]
35. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
Metser U; You J; McSweeney S; Freeman M; Hendler A
AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
[TBL] [Abstract][Full Text] [Related]
36. The utility of 18 F-FDG PET/CT for suspected recurrent breast cancer: impact and prognostic stratification.
Cochet A; David S; Moodie K; Drummond E; Dutu G; MacManus M; Chua B; Hicks RJ
Cancer Imaging; 2014 Apr; 14(1):13. PubMed ID: 25608599
[TBL] [Abstract][Full Text] [Related]
37. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy.
Veit-Haibach P; Antoch G; Beyer T; Stergar H; Schleucher R; Hauth EA; Bockisch A
Br J Radiol; 2007 Jul; 80(955):508-15. PubMed ID: 17537758
[TBL] [Abstract][Full Text] [Related]
38. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
39. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
[TBL] [Abstract][Full Text] [Related]
40. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
